Literature DB >> 21062987

High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.

Cornelis A M Van Bergen1, Caroline E Rutten, Edith D Van Der Meijden, Simone A P Van Luxemburg-Heijs, Ellie G A Lurvink, Jeanine J Houwing-Duistermaat, Michel G D Kester, Arend Mulder, Roel Willemze, J H Frederik Falkenburg, Marieke Griffioen.   

Abstract

Patients with malignant diseases can be effectively treated with allogeneic hematopoietic stem cell transplantation (allo-SCT). Polymorphic peptides presented in HLA molecules, the so-called minor histocompatibility antigens (MiHA), play a crucial role in antitumor immunity as targets for alloreactive donor T cells. Identification of multiple MiHAs is essential to understand and manipulate the development of clinical responses after allo-SCT. In this study, CD8+ T-cell clones were isolated from leukemia patients who entered complete remission after allo-SCT, and MiHA-specific T-cell clones were efficiently selected for analysis of recognition of a panel of EBV-transformed B cells positive for the HLA restriction elements of the selected T-cell clones. One million single nucleotide polymorphisms (SNP) were determined in the panel cell lines and investigated for matching with the T-cell recognition data by whole genome association scanning (WGAs). Significant association with 12 genomic regions was found, and detailed analysis of genes located within these genomic regions revealed SNP disparities encoding polymorphic peptides in 10 cases. Differential recognition of patient-type, but not donor-type, peptides validated the identification of these MiHAs. Using tetramers, distinct populations of MiHA-specific CD8+ T cells were detected, demonstrating that our WGAs strategy allows high-throughput discovery of relevant targets in antitumor immunity after allo-SCT.
Copyright © 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062987     DOI: 10.1158/0008-5472.CAN-10-1832

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Minor histocompatibility antigens are expressed in syncytiotrophoblast and trophoblast debris: implications for maternal alloreactivity to the fetus.

Authors:  Olivia J Holland; Caitlin Linscheid; Herbert C Hodes; Traci L Nauser; Melissa Gilliam; Peter Stone; Larry W Chamley; Margaret G Petroff
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

Review 2.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 3.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

Authors:  Jenny Zilberberg; Rena Feinman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

4.  LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.

Authors:  Margot J Pont; Willemijn Hobo; Maria W Honders; Simone A P van Luxemburg-Heijs; Michel G D Kester; Annemarie M van Oeveren-Rietdijk; Nicolaas Schaap; Hetty C de Boer; Cornelis A M van Bergen; Harry Dolstra; J H Frederik Falkenburg; Marieke Griffioen
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

5.  Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens.

Authors:  Jefferson L Lansford; Udara Dharmasiri; Shengjie Chai; Sally A Hunsucker; Dante S Bortone; James E Keating; Ian M Schlup; Gary L Glish; Edward J Collins; Gheath Alatrash; Jeffrey J Molldrem; Paul M Armistead; Benjamin G Vincent
Journal:  Blood Adv       Date:  2018-08-28

6.  Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

Authors:  Cornelis A M van Bergen; Simone A P van Luxemburg-Heijs; Liesbeth C de Wreede; Matthijs Eefting; Peter A von dem Borne; Peter van Balen; Mirjam H M Heemskerk; Arend Mulder; Fransiscus H J Claas; Marcelo A Navarrete; Wilhelmina M Honders; Caroline E Rutten; Hendrik Veelken; Inge Jedema; Constantijn J M Halkes; Marieke Griffioen; J H Frederik Falkenburg
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

7.  Identification of minor histocompatibility antigens based on the 1000 Genomes Project.

Authors:  Rimke Oostvogels; Henk M Lokhorst; Monique C Minnema; Maureen van Elk; Kelly van den Oudenalder; Eric Spierings; Tuna Mutis; Robbert M Spaapen
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

Review 8.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

9.  Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.

Authors:  Anniek B van der Waart; Noortje M P van de Weem; Frans Maas; Cynthia S M Kramer; Michel G D Kester; J H Frederik Falkenburg; Nicolaas Schaap; Joop H Jansen; Robbert van der Voort; Luca Gattinoni; Willemijn Hobo; Harry Dolstra
Journal:  Blood       Date:  2014-10-21       Impact factor: 22.113

Review 10.  Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.

Authors:  Saar Gill
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.